Add BrightSurf on Google Email

Scientists identify inhibition of a specific enzyme as a promising target to treat pancreatic cancer

Researchers have identified complement factor B as a promising target for pancreatic cancer treatment. Inhibiting this enzyme suppresses cancer growth, induces cellular senescence, and remodels the tumor immune microenvironment. The combination of CFB inhibition with chemotherapy and immunotherapy showed the greatest tumor suppression.

SourceElsevier·JournalAmerican Journal Of Pathology·TypeExperimental study·DateNov 9, 2026

Age may influence links between psychedelic use and mental health

A study of 1,088 adults aged 18 to 55 found that those who used classic psychedelics, such as psilocybin and LSD, in their younger years reported lower anxiety and depression scores than non-users, but this association weakened with age. The research, published in Scientific Reports, highlights the importance of age as a moderating fac...

SourceDurham University·JournalScientific Reports·TypeObservational study·DateNov 9, 2026

Experimental weight-loss drug eases painful knee osteoarthritis in two clinical trials

Phase 3 clinical trials involving over 1,000 participants found that those taking retatrutide, a new experimental weight-loss injectable drug, lost about a quarter of their body weight on average and experienced significant pain relief. The drug also showed benefits in reducing blood pressure, lipid levels, and systemic inflammation.

SourceNorthwestern University·JournalNew England Journal of Medicine·DateNov 8, 2026

New review in Chinese Medical Journal illuminates the crosstalk between epigenetics and metabolism in hepatocellular carcinoma

Researchers systematically summarize how epigenetic modifications and metabolic reprogramming interact to drive hepatocellular carcinoma. The review highlights the epigenetic-metabolism axis as a promising therapeutic target and offers new insights for treatment.

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalChinese Medical Journal·TypeSystematic review·DateOct 16, 2026

Black children at risk for severe form of asthma, new research shows

A new UVA study finds that Black children are more likely to develop severe asthma due to harmful inflammation, regardless of environmental factors. The research suggests tailored treatments for Black children with severe symptoms, and testing for high levels of T2 inflammation in all children with difficult-to-treat asthma.

SourceUniversity of Virginia Health System·JournalJournal of Allergy and Clinical Immunology: In Practice·DateOct 16, 2026

Penn engineers use AI, Reddit to identify potential side effects of unapproved new GLP-1

Researchers used AI to analyze nearly 150,000 Reddit posts about unapproved GLP-1 weight loss drug retatrutide, identifying potential side effects that differ from clinical trial results. The study found increased appetite to be the most frequently reported symptom, which contrasts with gastrointestinal complaints identified in Phase 2...

SourceUniversity of Pennsylvania School of Engineering and Applied Science·JournalJAMA Network Open·TypeData/statistical analysis·DateOct 15, 2026

Jawbone necrosis in advanced breast cancer: Finnish study highlights the importance of oral health

A nationwide Finnish registry study investigated medication-related osteonecrosis of the jaw in breast cancer patients receiving antiresorptive treatment. The study found that 12.6% of patients developed the condition, with associations between dental procedures and its risk. The findings emphasize the need for close collaboration betw...

SourceUniversity of Oulu, Finland·JournalClinical Oral Investigations·DateOct 14, 2026

LSD microdosing: Study indicates it makes women’s attention sharper, but no improvement in men

A pilot study found that low-dose LSD improves women's sustained attention, but has no effect on men's attention. The study, led by Iva Totomanova, involved 24 women and 24 men, and used a double-blind placebo-controlled design. The results suggest that people may respond differently to LSD depending on their sex, cognitive task, and c...

Digital alerts support timely treatment decisions of critically ill cardiac patients

Researchers found that well-designed digital alerts can assist clinicians in high-pressure situations, prompting them to make recommended treatment decisions and recognize when patients are deteriorating. The studies demonstrated the effectiveness of electronic health record alerts in the emergency department and cardiac intensive care...

SourceMichigan Medicine - University of Michigan·JournalJACC Case Reports·TypeObservational study·DateOct 6, 2026

New global survey shines a light on the patients who rely on plasma-derived medicines—and the donors who make them possible

A global survey of over 1,100 patients, caregivers, and healthcare providers found that 69% noticed a change in their health or someone they care for within a few months of plasma-derived medicine treatment, with 77% expressing gratitude to donors. The survey also revealed high confidence in plasma-derived medicines' safety and efficacy.

Chinese Medical Journal study reveals gallic acid inhibits prostate cancer progression via the NF-κB/KLF7/L1CAM Axis

Researchers discovered gallic acid suppresses tumor progression by targeting the NF-κB/KLF7/L1CAM axis in prostate cancer. The study demonstrated that gallic acid significantly impaired aggressive behaviors of PC-3 and LNCaP cells without toxicity to normal cells.

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalChinese Medical Journal·TypeExperimental study·DateOct 2, 2026

New daily orforglipron pill demonstrated cardiovascular safety in its largest and longest study of type 2 diabetes (ACHIEVE-4 study)

The ACHIEVE-4 study shows orforglipron pills offer superior weight loss and blood sugar control compared to insulin glargine, but with a higher gastrointestinal adverse event rate. Non-inferiority for cardiovascular safety and superiority for weight reduction were demonstrated.

New investigational drug combining eloralintide and tirzepatide (EloraTZP) led to weight loss of up to 23.3% in people living with obesity and type 2 diabetes

The phase 2b study evaluates the safety and efficacy of eloralintide in combination with tirzepatide, resulting in substantial weight loss and improvements in blood sugar control. The study demonstrated substantial weight loss and reduction in glycated haemoglobin (HbA1c) across different dosing combinations.

GLP-1 receptor agonist drugs have real benefits for children, adolescents and young adults with type 2 diabetes, real-world study concludes

Real-world study data from Germany, Austria and Luxembourg show that GLP-1 receptor agonist drugs improve weight (37% reduction ≥ 5%), blood sugar control (glycaemic improvement) and systolic blood pressure in children and adolescents with type 2 diabetes. These benefits remained significant after adjustment for other factors.

Women are and will be the predominant users of GLP-1 receptor agonists (GLP-1 RAs) in future – but much work still needed to analyse specific effects of these drugs in women and address equality in access globally

Women are more likely to experience weight loss and improved blood sugar control with GLP-1 RAs, but face higher rates of side effects and unequal access to treatment worldwide. Extensive research is needed to address these disparities and optimize treatment for women in various domains.

SourceEuropean Association for the Study of Diabetes·JournalThe Lancet Obstetrics, Gynaecology, & Women’s Health·DateSep 29, 2026

Review of available data shows mostly positive findings for preconception, pregnancy and postnatal use of GLP-1RA in women with diabetes, but with huge gaps in evidence that must be addressed

A systematic review of 43,000 women with diabetes exposed to GLP-1 RAs found no significant associations with preterm birth, stillbirth, or neonatal death, but evidence gaps remain for early pregnancy loss and postpartum use. Further research is needed to address these gaps and provide clearer evidence for women with diabetes

SourceEuropean Association for the Study of Diabetes·JournalThe Lancet Obstetrics, Gynaecology, & Women’s Health·DateSep 29, 2026

New amylin-based obesity drug petrelintide can deliver over 10% weight loss; less than GLP-1 / incretin drugs on average but with far fewer side effects

Petrelintide, an amylin-based obesity drug, shows significant weight loss of over 10% in a phase 2 trial, with fewer gastrointestinal side effects compared to GLP-1 drugs. The study also reveals improvements in key cardiovascular risk factors, such as blood pressure and lipid parameters.

SourceEuropean Association for the Study of Diabetes·JournalThe Lancet Diabetes & Endocrinology·DateSep 29, 2026

New triple agonist retatrutide produces substantial weight loss and improvements in blood sugar control in people living with obesity and type 2 diabetes – TRIUMPH-2 study

Retatrutide demonstrates substantial weight loss and improved blood sugar control in adults with overweight and type 2 diabetes, with 47% of participants losing at least 20% of their starting weight. The treatment also improves cardiometabolic risk factors and reduces inflammation.

Chinese Medical Journal evaluates triple regimen for HR+/HER2− advanced breast cancer

A phase Ib/II trial evaluated the triple combination of famitinib, dalpiciclib, and fulvestrant in HR+/HER2− breast cancer, meeting initial efficacy targets with a confirmed objective response rate of 51.9%. However, the regimen showed no superiority over standard first-line treatments and was terminated early due to safety concerns.

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalChinese Medical Journal·DateSep 28, 2026

Millions more people with overweight could benefit from GLP-1 drugs to protect heart health, Danish study suggests

A Danish study suggests that GLP-1 drugs could protect heart health in millions of people with overweight. The research found that individuals with a BMI of 25-26.9 and high remnant cholesterol and/or low-grade inflammation have a similar risk of coronary heart disease as those eligible for GLP-1 RAs for weight loss.

Loberamisal for acute ischemic stroke

A study published in JAMA found that intravenous loberamisal increased the proportion of patients with acute ischemic stroke achieving full functional outcomes at 90 days. The treatment resulted in a higher proportion of patients regaining full functional abilities compared to placebo.

SourceJAMA Network·JournalJAMA·DateSep 10, 2026

Deconstructing LSD for therapeutic discoveries

University of California, Davis researchers successfully synthesized new compounds with reduced hallucinogenic and cardiotoxic effects, identifying one compound with antipsychotic-like effects. By systematically deconstructing LSD, they uncovered the importance of the phenethylamine-like traits in producing hallucinogenic effects.

SourceUniversity of California - Davis·JournalProceedings of the National Academy of Sciences·DateSep 7, 2026

Faster path to treatment for deadly childhood dementia

Researchers have identified several existing TGA-approved medicines that could slow brain damage in children with Sanfilippo syndrome, a devastating childhood dementia. The study used lab-grown brain cells and AI to rapidly test approved drugs and pinpoint those that improve brain cell health.

SourceFlinders University·JournalNature Communications·TypeComputational simulation/modeling·DateAug 20, 2026

Resurgence of malaria in Ethiopia

A recent study by the Ethiopian Public Health Institute and the JAMA Network has identified emerging drug and diagnostic resistance variants as contributing factors to Ethiopia's malaria resurgence. The study highlights the need for continued monitoring and adaptation of treatment strategies to combat the growing malaria epidemic.

SourceJAMA Network·JournalJAMA·DateAug 20, 2026

Federal and industry sponsorship in US cancer clinical trials

A comparative study of 11,681 US cancer clinical trials reveals that industry-sponsored trials focus on single-agent drug therapies, while federally sponsored trials evaluate nontreatment interventions and rare cancer therapies. The study highlights the differences in trial design and objectives between industry and federal funding.

SourceJAMA Network·JournalJAMA Oncology·DateAug 20, 2026

One in 20 Australian women now receiving iron IVs

A new study found a 17-fold increase in intravenous iron use among Australian women aged 18-44, with over 82 million dollars spent on the treatment. The study highlights the growing awareness of iron deficiency's impact on women's health, but also raises questions about access to equitable treatment.

SourceFlinders University·JournalInternal Medicine Journal·TypeObservational study·DateAug 17, 2026

Alliance reports results from first randomized trial of a radiopharmaceutical in kidney cancer

The RadiCaL study, the first randomized trial of a radiopharmaceutical in kidney cancer, found that adding radium-223 to the standard of care does not improve skeletal event-free survival. Patients who received the combination treatment lived a median of 28.3 months, compared with 19.7 months for those who received cabozantinib alone.

SourceAlliance for Clinical Trials in Oncology·JournalJournal of Clinical Oncology·TypeExperimental study·DateAug 17, 2026

Teaching AI the biology of antibodies speeds drug discovery

By focusing on the specific regions of antibodies responsible for recognizing disease targets, the AI model improved binding affinity prediction and required fewer computational resources. This approach is similar to human-language AI models, where smaller domain-specific models trained on high-quality data can outperform larger ones.

SourceBoston University·TypeComputational simulation/modeling·DateAug 13, 2026

National socioeconomic status influences disease severity at treatment start and duration of treatment in patients with psoriatic arthritis and axial spondyloarthritis

A new study found that patients from wealthier European countries tend to start biologic treatments earlier but stop or switch treatment earlier, experiencing lower disease activity. The study highlights the importance of ensuring timely and equitable access to effective treatment for patients with PsA and axSpA.

SourceElsevier·JournalAnnals of the Rheumatic Diseases·TypeData/statistical analysis·DateAug 11, 2026